Soaring Biotech Stock Alert: AnPac Bio-Medical Science (NASDAQ: ANPC)

As other stocks plunged on Thursday, AnPac Bio-Medical Science (NASDAQ: ANPC) lost 0.37 points on 20,913. Diminishing demand for shares has obviously happened on that day. Today in premarket ANPC is surging by 20% after announcing positive results from a multi-year lung cancer prognosis and recurrence clinical study.

ANPC debuted in this year’s January with $10 per share IPO but it has slowly been losing points on a weekly basis while coronavirus stocks rocket at rapid rates. Lung cancer is a widespread disease and complex therapy development for the treatment may push the company’s stock upward.

Today ANPC rides above $5 and could grow further due to receiving high trust from long term investors. While it is cheap fund managing analysts may recommend it to consider as a strong buy stock. Along with other biotech stocks, ANPC has a volatile nature in growth. This week it grows but next could be worst for new shareholders.

Jack Dawkins

Finance and Tech Contributor